Versant Venture Capital VI, L.P., 10% Owner at Akero Therapeutics, Inc. (AKRO), sold 73,235 shares at $19.80 ($1.5M) on 2019-12-20, disclosed to the SEC on 2019-12-26.
Open-market sale of $1.5M AKRO by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.80 | 18,582 | $368K | 24.0% |
| 2 | $19.80 | 18,582 | $368K | 24.0% |
| 3 | $21.56 | 5,433 | $117K | 7.6% |
| 4 | $21.56 | 5,433 | $117K | 7.6% |
| 5 | $21.70 | 1,605 | $35K | 2.3% |
| 6 | $22.48 | 23,600 |
| $531K |
| 34.6% |
| Total | $20.97 avg | 73,235 | $1.5M | 100% |
| Filing → |
| GLUE | SELL | 2024-10-30 | $2.8M | — | Filing → |
| GLUE | SELL | 2024-09-24 | $14.8M | — | Filing → |
| TPST | SELL | 2024-08-12 | $1.4M | — | Filing → |